Clinical Trial

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Protocol Amendment History 1 change
minor Completion pushed: 2026-01 -> 2026-05 2026-04-02
Trial Details
NCT Number NCT05480384
Lead Sponsor Brown University
Collaborators: AstraZeneca
Conditions Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
Enrollment 1 participants
Start Date 2023-07-14
Primary Completion 2025-05-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-21